The use of liraglutide 3.0 mg daily in the management of overweight and obesity in people with schizophrenia, schizoaffective disorder and first episode psychosis: Results of a pilot randomized, double-blind, placebo-controlled trial.

Clare A WhicherHermione C PricePeter PhiriShanaya RathodKatharine Barnard-KellyKandala NgiangaKerensa ThorneCarolyn AsherRobert C PevelerJoanne McCarthyRichard Ian Gregory Holt

Published in: Diabetes, obesity & metabolism (2021)

This study supports the need for a larger randomized controlled trial to evaluate the use of liraglutide (maximum dose 3.0 mg daily) in the management of obesity in people with severe mental illness.

Keyphrases

mental illness
randomized controlled trial
double blind
study protocol
mental health
physical activity
clinical trial
metabolic syndrome
bipolar disorder
type diabetes
placebo controlled
insulin resistance
weight loss
early onset
phase iii
open label